Citius Oncology (CTOR) Retained Earnings (2021 - 2026)

Citius Oncology (CTOR) has reported Retained Earnings for 6 consecutive years, with $145.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings rose 59.11% year-over-year to $145.5 million in Q2 2026; TTM through Jun 2026 was $145.5 million, a 59.11% increase from a year earlier, with the FY2025 full-year figure at $108.9 million, up 27.5% from the prior year.
• Retained Earnings was $145.5 million for Q2 2026 at Citius Oncology, up from $131.4 million in the prior quarter.
• Over five years, Retained Earnings peaked at $145.5 million in Q2 2026 and troughed at -$3.0 million in Q2 2024.
• A 5-year average of $56.5 million and a median of $64.5 million in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings soared 175751.9% in 2023 and plunged 137461.86% in 2024, its largest moves.
• Over 5 years, Retained Earnings stood at $345266.0 in 2022, then plunged by 675.71% to -$2.0 million in 2023, then jumped by 4487.93% to $87.2 million in 2024, then surged by 46.73% to $128.0 million in 2025, then advanced by 13.68% to $145.5 million in 2026.
• The last three Retained Earnings figures came in at $145.5 million (Q2 2026), $131.4 million (Q1 2026), and $128.0 million (Q4 2025), per Business Quant data.